Skip to content
TheChatArchiveThe Chat Archive
Grok 4.1 Fast· xaiHugging Face Frontier Reasoning Traces

Provide an acute coronary syndrome (NSTEMI/STEMI/UA) guide: recognition and initial…

  1. User

    Provide an acute coronary syndrome (NSTEMI/STEMI/UA) guide: recognition and initial stabilization, diagnostic pathway (ECG/troponin), antithrombotic therapy and dosing, reperfusion strategies and timing, secondary prevention, discharge planning, and follow-up.

  2. Assistant

    Acute Coronary Syndrome (ACS) Guide

    ACS encompasses ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). This guide follows 2023 AHA/ACC guidelines. Always tailor to patient specifics; consult local protocols.

    1. Recognition and Initial Stabilization

    Clinical Recognition

    • Symptoms: Retrosternal chest pain/pressure (>20 min, new/worsening), radiating to arm/jaw/neck; dyspnea, nausea, diaphoresis, fatigue. Atypical in women, elderly, diabetics (e.g., jaw pain, epigastric discomfort).
    • Risk Factors: Age >55M/>65F, HTN, DM, smoking, dyslipidemia, family history, prior CAD.
    • High-Risk Features: Hemodynamic instability, sustained VT, new heart failure, syncope.

    Initial Stabilization (ABCDE Approach)

    • Airway/Breathing: O2 if SpO2 <90% or respiratory distress (avoid routine O2).
    • Circulation:
      • IV access, continuous monitoring (ECG, BP, HR).
      • Aspirin: 162-325 mg chewed stat (unless contraindicated).
      • Nitroglycerin: 0.4 mg SL q5min x3 if ongoing pain, SBP >90 mmHg (avoid in RV infarct, recent PDE5i, severe AS).
      • Morphine: 2-5 mg IV if pain persists (controversial; use sparingly).
    • Disability/Exposure: Bed rest, warmth.
    • Transfer: To PCI-capable center if STEMI.

    2. Diagnostic Pathway

    ECG (Door-to-ECG <10 min)

    • STEMI: ≥1 mm ST-elevation in ≥2 contiguous leads (or new LBBB); posterior (V7-V9 ST-depression + elevation).
    • NSTEMI/UA: ST-depression/T-wave inversion, normal, or nonspecific.
    • Repeat ECG q15-30 min if initial nondiagnostic + ongoing pain.

    Cardiac Biomarkers

    TestTiming/DetailsInterpretation
    High-Sensitivity Troponin (hs-Tn)Stat + 1-3h serial (or 0/1h/3h algorithm)>99th %ile URL = MI if rise/fall + symptoms/ECG/echo changes. hs-Tn preferred for speed.
    CK-MBIf troponin unavailableLess specific.
    • ACS Confirmed: Symptoms + ECG/Biochem changes.
    • Risk Stratify NSTE-ACS: TIMI/GRACE score (high-risk: ≥3 TIMI = early invasive).

    Echo if available: RWMA, EF, complications (MR, VSD, tamponade).

    3. Antithrombotic Therapy and Dosing

    All ACS: Dual Antiplatelet Therapy (DAPT) + anticoagulant.

    Antiplatelet Agents

    AgentLoading DoseMaintenance DoseNotes
    Aspirin162-325 mg chewed81 mg daily indefinitelyAll patients.
    P2Y12 Inhibitors
    - Ticagrelor (preferred)180 mg90 mg BID x12 mo (then 60 mg BID if PCI)Avoid in prior ICH; dyspnea common.
    - Prasugrel60 mg10 mg daily (5 mg if <60 kg or ≥75y)Avoid if prior TIA/stroke, age ≥75y.
    - Clopidogrel600 mg75 mg dailyIf ticagrelor/prasugrel CI; CYP2C19 test if high risk.
    • DAPT Duration: 12 mo post-ACS/PCI; extend if low bleed risk.

    Anticoagulants (Upstream in NSTE-ACS; during PCI)

    AgentDose (ACS)AdjustmentsDuration
    UFHBolus 60 U/kg IV (max 4000 U); inf 12 U/kg/h (max 1000 U/h)aPTT 1.5-2x controlPCI or 48h
    Enoxaparin1 mg/kg SC q12h1 mg/kg q24h if CrCl <3048h or hosp
    Bivalirudin0.75 mg/kg bolus; 1.75 mg/kg/h infCrCl adjustPCI only
    Fondaparinux2.5 mg SC dailyAvoid if CrCl <3048h or discharge
    • Parenteral until PCI/revasc or 48h.

    4. Reperfusion Strategies and Timing

    STEMI (Primary Reperfusion Goal)

    StrategyTiming (First Medical Contact)Preferred Population
    Primary PCI<90 min (door-to-balloon <90 min)All; radial access preferred.
    Fibrinolysis<30 min if PCI delay >120 minIf PCI >120 min away; TNK-tPA 40 mg IV <100 kg.
    - ContraindicationsActive bleed, recent stroke/CVA, etc.
    • Transfer: If non-PCI center, <120 min to PCI.
    • Rescue PCI if fibrinolysis failure (<90 min ST-res).

    NSTE-ACS (Ischemia-Guided vs. Invasive)

    RiskStrategyTiming
    High (GRACE >140, TIMI ≥3)Invasive (cath)<24h
    IntermediateInvasive<72h
    LowConservative (meds ± noninvasive test)Discharge or outpatient
    • Glycoprotein IIb/IIIa (e.g., tirofiban) if high thrombus burden (rare now).

    5. Secondary Prevention

    Start in-hospital; optimize at discharge.

    Therapy ClassAgents/TargetsIndications/All Patients Unless CI
    AntiplateletDAPT as aboveAll.
    StatinHigh-intensity (atorva 40-80 mg, rosuva 20-40 mg); LDL <70 mg/dLAll. PCSK9i if LDL >70 on max statin.
    Beta-BlockerMetoprolol succ 25-50 mg BID; target HR 50-60All (EF <40% lifelong).
    ACEI/ARBLisinopril 5-40 mg; or losartanEF ≤40%, HTN, DM, CKD.
    Aldosterone AntagSpironolactone 25 mgEF ≤40% + DM or HF.
    SGLT2i/GLP1RAEmpagliflozin/Dapagliflozin; semaglutideDM/CV risk.
    • Lifestyle: Smoking cessation, diet (Med), exercise (CR 36 sessions), BP <130/80, A1c <7%.

    6. Discharge Planning

    • Criteria: Hemodynamically stable, <24h rest angina, successful revasc, no arrhythmia/major complications.
    • Education:
      • Med adherence (pill box), symptoms to return for (worsening pain, SOB).
      • Activity: Gradually increase; avoid heavy lifting x1-2 wk post-PCI.
      • Diet: Low sat fat/salt; alcohol moderation.
    • Meds at Discharge (table format as above).
    • Cardiac Rehab Referral: All eligible.
    • Devices: ICD if EF ≤35% >40 days post-MI.

    7. Follow-Up

    • Timing: 1-2 wk post-discharge (primary care/cardio); then 4-6 wk for echo/EF if indicated.
    • Tests: Lipids 4-6 wk; echo if EF unknown; stress test if med Rx for NSTE.
    • Long-Term: Annual flu vaccine; monitor for HF, recurrent ischemia.
    • Dual Therapy Switch: Ticagrelor + riva/bro 1-3 mo post-PCI if high bleed risk.

    Key Pearls: Time is muscle. Radial PCI reduces bleed. Multidisciplinary team. Individualize based on age/bleed risk (e.g., PRECISE-DAPT score). For updates, reference AHA/ACC or ESC guidelines. This is not medical advice—consult a clinician.